Coronavirus (COVID-19) information for Dana-Farber patients & families Learn more
Please note that some translations using Google Translate may not be accurately represented and downloaded documents cannot be translated. Dana-Farber assumes no liability for inaccuracies that may result from using this third-party tool, which is for website translation and not clinical interactions. You may request a live medical interpreter for a discussion about your care.
In addition to providing patients first-class treatment, our team is dedicated to learning more about ocular melanoma and potential new therapies through clinical research. Areas of focus in our research include:
A Phase Ib, Open-label Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Antitumor Activities of IN10018 as Monotherapy and Combination Therapy in Subjects with Metastatic MelanomaProtocol #:19-889Trial Description: This is a phase Ib, open label clinical study to evaluate the safety, tolerability, PK and antitumor activities of IN10018 as monotherapy and in combination with cobimetinib in subjects with metastatic ocular (uveal) melanoma and NRAS-mutant metastatic melanoma.
New Patient Appointments